{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T18:15:40Z","timestamp":1767982540307,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T00:00:00Z","timestamp":1617580800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["In Silico Pharmacol."],"DOI":"10.1007\/s40203-021-00083-0","type":"journal-article","created":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T10:02:53Z","timestamp":1617616973000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical pharmacokinetic study of latrepirdine via in silico sublingual administration"],"prefix":"10.1007","volume":"9","author":[{"given":"Joana","family":"Santos","sequence":"first","affiliation":[]},{"given":"Lu\u00edsa","family":"Lobato","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1283-1042","authenticated-orcid":false,"given":"Nuno","family":"Vale","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2021,4,5]]},"reference":[{"issue":"3","key":"83_CR1","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1080\/10837450902891295","volume":"41","author":"MS Benedetti","year":"2009","unstructured":"Benedetti MS, Whomsley R, Poggesi I, Cawello W, Mathy FX, Delporte ML et al (2009) Drug metabolism and pharmacokinetics. Drug Metab Rev 41(3):344\u2013390","journal-title":"Drug Metab Rev"},{"issue":"8","key":"83_CR2","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1358\/dnp.2010.23.8.1500435","volume":"23","author":"I Bezprozvanny","year":"2010","unstructured":"Bezprozvanny I (2010) The rise and fall of Dimebon. Drug News Perspect 23(8):518\u2013523","journal-title":"Drug News Perspect"},{"issue":"12","key":"83_CR3","doi-asserted-by":"publisher","first-page":"4977","DOI":"10.1021\/jm4004285","volume":"57","author":"A Cherkasov","year":"2015","unstructured":"Cherkasov A, Muratov EN, Fourches D, Varnek A, Igor I, Cronin M et al (2015) NIH public access. J Med Chem 57(12):4977\u20135010","journal-title":"J Med Chem"},{"issue":"8","key":"83_CR4","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s11095-016-1922-4","volume":"33","author":"ML Chew","year":"2016","unstructured":"Chew ML, Mordenti J, Yeoh T, Ranade G, Qiu R, Fang J et al (2016) Minimization of CYP2D6 polymorphic differences and improved bioavailability via transdermal administration: latrepirdine example. Pharm Res 33(8):1873\u20131880","journal-title":"Pharm Res"},{"key":"83_CR5","doi-asserted-by":"crossref","unstructured":"Daga PR, Bolger MB, Haworth IS, Clark RD, Martin EJ (2018) Physiologically based pharmacokinetic modeling in lead optimization. 1. Evaluation and adaptation of gastroplus to predict bioavailability of medchem series. Mol Pharm.15(3):821\u201330.","DOI":"10.1021\/acs.molpharmaceut.7b00972"},{"issue":"9634","key":"83_CR6","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S0140-6736(08)61074-0","volume":"372","author":"RS Doody","year":"2008","unstructured":"Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO et al (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled study. Lancet 372(9634):207\u2013215","journal-title":"Lancet"},{"key":"83_CR7","doi-asserted-by":"crossref","unstructured":"Eckert SH, Gaca J, Kolesova N, Friedland K, Gunter P (2018) Mitochondrial pharmacology of dimebon (Latrepirdine) calls for a new look at its possible therapeutic potential in Alzheimer \u2019 s Disease. Aging Dis.","DOI":"10.14336\/AD.2017.1014"},{"issue":"11","key":"83_CR8","doi-asserted-by":"publisher","first-page":"693","DOI":"10.3390\/biom9110693","volume":"9","author":"A Ferreira","year":"2019","unstructured":"Ferreira A, Lapa R, Vale N (2019) Combination of gemcitabine with cell-penetrating peptides: a pharmacokinetic approach using in silico tools. Biomolecules 9(11):693","journal-title":"Biomolecules"},{"issue":"1","key":"83_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jps.2600810102","volume":"81","author":"D Harris","year":"1992","unstructured":"Harris D, Robinson JR (1992) Drug delivery via the mucous membranes of the oral cavity. J Pharm Sci 81(1):1\u201310","journal-title":"J Pharm Sci"},{"issue":"6","key":"83_CR10","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1111\/j.1476-5381.2010.01127.x","volume":"162","author":"JP Hughes","year":"2011","unstructured":"Hughes JP, Rees SS, Kalindjian SB, Philpott KL (2011) Principles of early drug discovery. Br J Pharmacol 162(6):1239\u20131249","journal-title":"Br J Pharmacol"},{"issue":"1","key":"83_CR11","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.ejps.2013.09.008","volume":"57","author":"ES Kostewicz","year":"2014","unstructured":"Kostewicz ES, Aarons L, Bergstrand M, Bolger MB, Galetin A, Hatley O et al (2014) PBPK models for the prediction of in vivo performance of oral dosage forms. Eur J Pharm Sci 57(1):300\u2013321","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"83_CR12","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1515\/revneuro-2017-0006","volume":"28","author":"S Kozlov","year":"2017","unstructured":"Kozlov S, Afonin A, Evsyukov I, Bondarenko A (2017) Alzheimer\u2019s disease: as it was in the beginning. Rev Neurosci 28(8):825\u2013843","journal-title":"Rev Neurosci"},{"key":"83_CR13","doi-asserted-by":"crossref","unstructured":"Lombardo F, Desai P V, Arimoto R, Desino KE, Fischer H, Keefer CE, et al (2017) In silico absorption, distribution, metabolism, excretion, and pharmacokinetics (ADME-PK): utility and best practices. An industry perspective from the international consortium for innovation through quality in pharmaceutical development. J Med Chem 60(22):9097\u20139113.","DOI":"10.1021\/acs.jmedchem.7b00487"},{"key":"83_CR14","doi-asserted-by":"crossref","unstructured":"Maddison JE, Page SW, Dyke TM (2008) Chapter 2\u2014Clinical pharmacokinetics. In: Atkinson AJ, Abernethy DR, Daniels CE, Dedrick RL, Markey SPBT-P of CP (Second E, editors) Small animal clinical pharmacology.Academic Press, Burlington, p. 27\u201340","DOI":"10.1016\/B978-070202858-8.50004-X"},{"issue":"4","key":"83_CR15","first-page":"27","volume":"46","author":"IA Matveeva","year":"1983","unstructured":"Matveeva IA (1983) Action of dimebon on histamine receptors. Farmakol Toksikol 46(4):27\u201329","journal-title":"Farmakol Toksikol"},{"issue":"8","key":"83_CR16","doi-asserted-by":"publisher","first-page":"483","DOI":"10.2165\/11592400-000000000-00000","volume":"50","author":"O Pelkonen","year":"2011","unstructured":"Pelkonen O, Turpeinen M, Raunio H (2011) In vivo-in vitro-in silico pharmacokinetic modelling in drug development current status and future directions. Clin Pharmacokinet 50(8):483\u2013491","journal-title":"Clin Pharmacokinet"},{"key":"83_CR17","doi-asserted-by":"crossref","unstructured":"Rehfeld A, Nylander M, Karnov K (2017) The digestive system II: the associated organs. Compen Histol:475\u2013493.","DOI":"10.1007\/978-3-319-41873-5_22"},{"key":"83_CR18","unstructured":"Simulations Plus I (2011) GastroPlus Manual. 9294: 661\u2013723"},{"issue":"11","key":"83_CR19","first-page":"263","volume":"3","author":"N Toomula","year":"2011","unstructured":"Toomula N, Sathish kumar D, Kumar A, Phaneendra M, (2011) Role of pharmacokinetic studies in drug discovery. J Bioequival Bioavail 3(11):263\u20137","journal-title":"J Bioequival Bioavail"},{"key":"83_CR20","doi-asserted-by":"crossref","unstructured":"Vrbanac J, Slauter (2013) ADME in drug discovery. In: A Comprehensive Guide to Toxicology in Preclinical Drug Development. Elsevier Inc. pp 3\u201330.","DOI":"10.1016\/B978-0-12-387815-1.00002-2"},{"key":"83_CR21","doi-asserted-by":"crossref","unstructured":"Waller DG, Sampson AP (2018) Pharmacokinetics. In: Waller DG, Sampson APBT-MP and T (Fifth E, editors) Medical pharmacology and therapeutics [Internet]. Elsevier. pp 33\u201362.","DOI":"10.1016\/B978-0-7020-7167-6.00002-6"},{"key":"83_CR22","doi-asserted-by":"crossref","unstructured":"Wang Y, Zuo Z, Chen X, Tomlinson B, Chow MSS (2010) European Journal of Pharmaceutical Sciences Improving sublingual delivery of weak base compounds using pH max concept: application to propranolol 39:272\u2013278","DOI":"10.1016\/j.ejps.2009.12.011"},{"key":"83_CR23","doi-asserted-by":"crossref","unstructured":"Wang Y, Wang Z, Zuo Z, Tomlinson B, Lee BTK, Bolger MB, et al (2013) Clinical Pharmacokinetics of Buffered Propranolol Sublingual Tablet (PromptolTM)\u2014application of a New \u201c Physiologically Based \u201d Model to Assess Absorption and Disposition. 15(3).","DOI":"10.1208\/s12248-013-9479-1"}],"container-title":["In Silico Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-021-00083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40203-021-00083-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40203-021-00083-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T16:12:26Z","timestamp":1668701546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40203-021-00083-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,5]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83"],"URL":"https:\/\/doi.org\/10.1007\/s40203-021-00083-0","relation":{},"ISSN":["2193-9616"],"issn-type":[{"value":"2193-9616","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,5]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declaration"}},{"value":"All authors have no conflicts of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"29"}}